Name: Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model (Video) | JoVE Journal
Uploaded: 2020-09-03T13:00:00.000+00:00
Duration: 7 min 50 s
Description: Discover a method for delayed intramyocardial stem cell delivery in a murine ischemia reperfusion injury model. This technique circumvents the initial immune response to improve cell viability and retention.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

playerTrialDesktop

The experiments were performed on female C57BL/6 mice, age 10-12 weeks and 20-25 g body weight. All animal procedures complied with the standards stated in the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, National Academy of Sciences, Bethesda, MD, USA) and were approved by the Mayo Clinic College of Medicine Institutional Animal Care and Use Committee (IACUC).
1. Preparation and intubation
<ol>
	<li>Autoclave all surgical instruments before surgery. If multiple surgeries are to be performed in one session, clean the instruments after each animal and re-sterilize using a hot bead sterilizer.</li>
	<li>Anesthetize the mice with 3.5-4% isoflurane at 1 L/min O2 in an induction chamber.</li>
	<li>Administer Buprenorphine SR 1 mg/kg (analgesic) subcutaneously, weigh the animal, and input the weight into the ventilator.</li>
	<li>Shave the left side of the chest from the sternum to the level of the shoulder and apply depilatory cream to remove excess fur.</li>
	<li>For the ischemia reperfusion procedure maintain the positive end-expiratory pressure (PEEP) on the ventilator at 2 cmH2O. For the delayed injection of cells procedure change the PEEP to 3 cmH2O to prevent lung collapse.</li>
	<li>Intubate the animal using a 20 G endotracheal tube, transfer to a controlled heating pad to maintain a body temperature of 35-37 &#176;C.</li>
	<li>Place the mouse on a ventilator in lateral recumbency with cranial end on the left and caudal end on the right.</li>
	<li>Maintain anesthesia at 2-2.5% isoflurane at 1 L/min O2 for the remainder of the procedure.</li>
	<li>Scrub the surgical area alternating between povidone-iodine and alcohol swabs three times and apply ophthalmic ointment to both eyes.</li>
</ol>
2. Ischemia reperfusion injury
<ol>
	<li>Using a #10 blade scalpel make a vertical incision 2.5 mm to right of the leftmost nipple in the field of view.</li>
	<li>Using scissors cut through the superficial muscle layers until the intercostal muscles and ribs are visible.</li>
	<li>While lifting the ribs and surrounding tissue, cut through the intercostal space between the 4th and 5th ribs, then insert the eyelid retractor into the open space.</li>
	<li>Retract the pericardium using curved forceps, moving the lung upwards and out of view.</li>
	<li>Visualize LAD artery and, using a 9-0 nylon suture, pass through the myocardium beneath the artery 2.5 mm distal to the left auricle and tie a loose square knot.</li>
	<li>Cut 1 cm of polyethylene tubing and place it within the loose knot.</li>
	<li>Secure the suture around the tubing, confirm ischemia, then release after 35 min. 
	NOTE: Confirm ischemia by pallor and ventricular arrhythmia.</li>
	<li>After releasing the ligation and removing the tubing, wait for 5 min to confirm reperfusion of the myocardium.</li>
	<li>Place a 24 G I.V. catheter tube into the thoracic cavity one intercostal space to right of the opening.</li>
	<li>Close the intercostal incision with a 6-0 absorbable suture in a simple interrupted pattern.</li>
	<li>Close the muscle layer with a 6-0 absorbable suture in a continuous suture pattern.</li>
	<li>After closing the superficial muscle layer, remove the chest tube while withdrawing the air from thoracic cavity using a 1 mL tuberculin syringe.</li>
	<li>Close the skin incision with a 6-0 absorbable suture in a continuous horizontal mattress pattern 
	NOTE: Nylon sutures and a discontinuous suture pattern may also be used for the skin layer.</li>
	<li>Administer 1.5 mL of warm saline subcutaneously and apply triple-antibiotic ointment to the incision site to prevent infection.</li>
	<li>Turn off isoflurane and allow the animal to breathe through the ventilator on 100% O2 until it can breathe continuously without aid.</li>
	<li>Transfer the mouse to a bedding-free cage or a cage with covered bedding (paper towel or drape) on a warm pad with a temperature of 35-37 &#176;C until fully recovered.</li>
</ol>
3. Mouse mesenchymal stem cell delivery
NOTE: The strain of mice used for the procedure are an inbred line and are deemed genetically identical. The mesenchymal stem cells were obtained from animals of the same strain and, by protocol design, immunosuppression was not induced1.
<ol>
	<li>Complete the preparation and intubation steps as done previously for the first procedure.</li>
	<li>Remove the suture from the skin layer using scissors and forceps.</li>
	<li>With a #10 scalpel, make an incision in the same location as the previous surgery.</li>
	<li>Continue to use the scalpel to cut through scar tissue until muscle layer suture is visible</li>
	<li>Using the scissors and forceps remove the suture and cut the muscle layer open.</li>
	<li>Visualize and remove the sutures holding the ribs together and continue cutting through the intercostal muscle from the previous incision. 
	NOTE: The lungs may have adhered to the chest wall, if this occurs, use blunt or curved forceps to carefully separate and release them.</li>
	<li>Place the eyelid retractor into the intercostal space and locate the area of the previous ligation.</li>
	<li>Load the mesenchymal stem cells (3.0 x 105), suspended in 20 &#181;L PBS, into a 30 G insulin syringe, bend the needle slightly as needed for the proper angle to inject. 
	NOTE: Mesenchymal stem cells (MSCs) were isolated from the adipose tissue of 4-6-week-old C56BL/6 mice. Early passage cells (p3) were transduced with a vector expressing the firefly luciferase gene under the CMV promoter to allow in vivo cell viability monitoring. Adipose-derived mouse MSC were characterized by flow cytometry and the cells were positive for CD44, CD29, CD90 and CD105 but negative for the hematopoietic marker CD4514. Prior to the injection, MSCs were cultured for at least one passage to avoid the loss of cells from the thawing process.</li>
	<li>Moving in the direction from the apex towards the base of the heart insert the syringe into the peri-infarct region until the needle opening is completely inside the myocardium.</li>
	<li>Once inside slowly inject the cells into the myocardium, wait 3 s, then remove the needle.</li>
	<li>Observe the heart closely for 3 min to be sure of no abnormal reactions to the cells such as ventricular fibrillation.</li>
	<li>Place a 24 G IV catheter tube into the thoracic cavity one intercostal space to right of the opening.</li>
	<li>Close the intercostal, muscle, and skin layers and remove the chest tube in the same method as the first procedure.</li>
	<li>Administer 1.5 mL of warm saline subcutaneously and apply triple-antibiotic ointment to the incision site to prevent infection.</li>
	<li>Turn off isoflurane and allow animal to breathe through the ventilator on 100% O2 until it is able to breathe continuously without aid.</li>
	<li>Transfer the mouse to a bedding-free cage or a cage with covered bedding (paper towel or drape) on a warm pad with a temperature of 35-37 &#176;C until fully recovered.</li>
</ol>
4. Post-operative care following both procedures
<ol>
	<li>Observe the animal continuously until spontaneous breathing, sternal recumbency and normal movement is established.</li>
	<li>Continue observation every 15-30 min for at least 3 h on the day of the surgery.</li>
	<li>Check the mice for wound dehiscence or abnormal pain once daily for 5 days, then 2-3 times weekly.</li>
	<li>If the animal shows signs of pain (i.e. arched back, minimal movement, grimacing, or scruffy fur) after 72 h post-op, provide an additional dose of the Buprenorphine SR analgesic.</li>
</ol>

<ol><li>Franchi, F., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+Myocardial+Microenvironment+Modulates+the+Biology+of+Transplanted+Mesenchymal+Stem+Cells%5BTitle%5D)+AND+%22Molecular+Imaging+Biology%22%5BJournal%5D)">The Myocardial Microenvironment Modulates the Biology of Transplanted Mesenchymal Stem Cells.</a> Molecular Imaging Biology. , (2020).</li>
<li>Bergmann, O., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Evidence+for+cardiomyocyte+renewal+in+humans%5BTitle%5D)+AND+%22Science%22%5BJournal%5D)">Evidence for cardiomyocyte renewal in humans.</a> Science. 324 (5923), 98-102 (2009).</li>
<li>Writing Group, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Heart+Disease+and+Stroke+Statistics-2016+Update%3A+A+Report+From+the+American+Heart+Association%5BTitle%5D)+AND+%22Circulation%22%5BJournal%5D)">Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association.</a> Circulation. 133 (4), 38(2016).</li>
<li>Gersh, B. J., Simari, R. D., Behfar, A., Terzic, C. M., Terzic, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Cardiac+cell+repair+therapy%3A+a+clinical+perspective%5BTitle%5D)+AND+%22Mayo+Clinic+Protocol%22%5BJournal%5D)">Cardiac cell repair therapy: a clinical perspective.</a> Mayo Clinic Protocol. 84 (10), 876-892 (2009).</li>
<li>Terzic, A., Behfar, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Regenerative+heart+failure+therapy+headed+for+optimization%5BTitle%5D)+AND+%22European+Heart+Journal%22%5BJournal%5D)">Regenerative heart failure therapy headed for optimization.</a> European Heart Journal. 35 (19), 1231-1234 (2014).</li>
<li>Beegle, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Hypoxic+preconditioning+of+mesenchymal+stromal+cells+induces+metabolic+changes%2C+enhances+survival%2C+and+promotes+cell+retention+in+vivo%5BTitle%5D)+AND+%22Stem+Cells%22%5BJournal%5D)">Hypoxic preconditioning of mesenchymal stromal cells induces metabolic changes, enhances survival, and promotes cell retention in vivo.</a> Stem Cells. 33 (6), 1818-1828 (2015).</li>
<li>Kubli, D. A., Gustafsson, A. B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Mitochondria+and+mitophagy%3A+the+yin+and+yang+of+cell+death+control%5BTitle%5D)+AND+%22Circulation+Research%22%5BJournal%5D)">Mitochondria and mitophagy: the yin and yang of cell death control.</a> Circulation Research. 111 (9), 1208-1221 (2012).</li>
<li>Psaltis, P. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Noninvasive+monitoring+of+oxidative+stress+in+transplanted+mesenchymal+stromal+cells%5BTitle%5D)+AND+%22JACC+Cardiovascular+Imaging%22%5BJournal%5D)">Noninvasive monitoring of oxidative stress in transplanted mesenchymal stromal cells.</a> JACC Cardiovascular Imaging. 6 (7), 795-802 (2013).</li>
<li>Peet, C., Ivetic, A., Bromage, D. I., Shah, A. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Cardiac+monocytes+and+macrophages+after+myocardial+infarction%5BTitle%5D)+AND+%22Cardiovasc+Research%22%5BJournal%5D)">Cardiac monocytes and macrophages after myocardial infarction.</a> Cardiovasc Research. 16 (6), 1101-1112 (2020).</li>
<li>Swirski, F. K., Nahrendorf, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Cardioimmunology%3A+the+immune+system+in+cardiac+homeostasis+and+disease%5BTitle%5D)+AND+%22Nature+Reviews+Immunology%22%5BJournal%5D)">Cardioimmunology: the immune system in cardiac homeostasis and disease.</a> Nature Reviews Immunology. 18 (12), 733-744 (2018).</li>
<li>Zhang, Z., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Mesenchymal+Stem+Cells+Promote+the+Resolution+of+Cardiac+Inflammation+After+Ischemia+Reperfusion+Via+Enhancing+Efferocytosis+of+Neutrophils%5BTitle%5D)+AND+%22Journal+of+the+American+Heart+Association%22%5BJournal%5D)">Mesenchymal Stem Cells Promote the Resolution of Cardiac Inflammation After Ischemia Reperfusion Via Enhancing Efferocytosis of Neutrophils.</a> Journal of the American Heart Association. 9 (5), 014397(2020).</li>
<li>Saxena, A., Russo, I., Frangogiannis, N. G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Inflammation+as+a+therapeutic+target+in+myocardial+infarction%3A+learning+from+past+failures+to+meet+future+challenges%5BTitle%5D)+AND+%22Translational+Research%22%5BJournal%5D)">Inflammation as a therapeutic target in myocardial infarction: learning from past failures to meet future challenges.</a> Translational Research. 167 (1), 152-166 (2016).</li>
<li>Prabhu, S. D., Frangogiannis, N. G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+Biological+Basis+for+Cardiac+Repair+After+Myocardial+Infarction%3A+From+Inflammation+to+Fibrosis%5BTitle%5D)+AND+%22Circulation+Research%22%5BJournal%5D)">The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis.</a> Circulation Research. 119 (1), 91-112 (2016).</li>
<li>Dominici, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Minimal+criteria+for+defining+multipotent+mesenchymal+stromal+cells.+The+International+Society+for+Cellular+Therapy+position+statement%5BTitle%5D)+AND+%22Cytotherapy%22%5BJournal%5D)">Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.</a> Cytotherapy. 8 (4), 315-317 (2006).</li>
</ol>

The authors have nothing to disclose.

Over 85 million people worldwide are affected by cardiovascular disease3. The high prevalence of these ischemic events warrants further development and expansion of alternative therapies for promoting the regeneration of damaged tissue. Traditional methods utilize the ischemia reperfusion procedure in an acute setting with subsequent administration of therapeutics1. Inflammatory reactions are at its peak between 3-4 days postdating a cardiac ischemic event, with infiltratio...

Cardiovascular disease remains the most common cause of morbidity and mortality worldwide. Cardiac ischemic events have been found to be detrimental to the overall function of the myocardium and surrounding cells1. Only&#160;&#160; &#820;0.45-1.0% of cardiomyocytes will regenerate every year after myocardial damage occurs2. Despite the growing demand and inherent focus on developing treatments, therapies aiding in the regeneration of injured tissue have been difficult to establish and still require further optimization3,4,5. Stem cell therapies have been introduced as an alternative path to rejuvenate damaged tissue after an ischemic event; however, advancement of these therapies has been challenged by the limited survival and retention of the cells to an injured area6.
The microenvironment of the heart after an ischemic event can be characterized as hypoxic, pro-oxidant, and pro-inflammatory, presenting hostile conditions for therapeutic stem cells to adapt to for survival7,8. As an immune response is triggered following injury, na&#239;ve lymphocytes, macrophages, neutrophils and mast cells attempt to repair the damage by removing dying cells and modulating the process for tissue remodeling9,10,11. Within the first 3 days post-ischemia, inflammation is at its peak with the release of pro-inflammatory cytokines with high numbers of neutrophils and monocytes in the area10,12. After 7 days, much of the inflammation has subsided and the transition to reparative cells begins, continuing until the remodeling cascade is complete, approximately 14 days in mice13. Our surgical method is a potential alternative approach to the introduction of biologics into the myocardium to bypass the peak innate immune response after ischemia reperfusion injury. At the same time, it will allow for the study of any treatments in a condition of subacute/chronic ischemia where there may be different variables to consider compared to acute myocardial infarction.

<table><tbody><tr><td>0.9% NaCl Irrigation, USP</td><td>Baxter</td><td>0338-0048-04</td><td></td></tr><tr><td>11x12&quot; Press n&#039; Seal surgical drape, autoclavable</td><td>SAI Infusion Technologies</td><td>PSS-SD</td><td></td></tr><tr><td>24G 3/4&quot; IV catheter tube</td><td>Jelco</td><td>4053</td><td></td></tr><tr><td>28G x 1/2&quot; 1mL allergy syringe</td><td>BD</td><td>305500</td><td>Injection of analgesic</td></tr><tr><td>30G x 1/2&quot; 3/10cc insulin syringe</td><td>Ulticare</td><td>08222.0933.56</td><td>Injection of stem cells</td></tr><tr><td>6-0 S-29, 12&quot; Vicryl suture</td><td>Ethicon</td><td>J556G</td><td>Intercostal, superficial muscle and skin layer incision closure</td></tr><tr><td>9-0 BV100-4, 5&quot; Ethilon suture</td><td>Ethicon</td><td>2829G</td><td>Ligation of the LAD artery</td></tr><tr><td>Absorbent underpad</td><td>Thermo Fischer Scientific</td><td>14-206-64</td><td>For underneath the animal</td></tr><tr><td>Alcohol prep pads, 2 ply, medium</td><td>Coviden</td><td>6818</td><td></td></tr><tr><td>Anti-fog face mask</td><td>Halyard</td><td>49235</td><td></td></tr><tr><td>Bonn Strabismus scissors, curved, blunt</td><td>Fine Science Tools</td><td>14085-09</td><td></td></tr><tr><td>Buprenorphine HCL SR LAB 1mg/ml, 5 ml</td><td>ZooPharm Pharmacy</td><td></td><td>Buprenorphine narcotic analgesic formulated in a polymer that slows absorption extending duration of action (72 hours duration of activity).</td></tr><tr><td>Castroviejo needle holders, curved</td><td>Fine Science Tools</td><td>12061-01</td><td></td></tr><tr><td>Curity sterile gauze sponges</td><td>Coviden</td><td>397310</td><td></td></tr><tr><td>Delicate suture tying forceps, 45 angle bent</td><td>Fine Science Tools</td><td>11063-07</td><td></td></tr><tr><td>Electric Razor</td><td>Wahl</td><td></td><td>Fur removal</td></tr><tr><td>Isoflurane 100 ml</td><td>Cardinal Health</td><td>PI23238</td><td>Anesthetic</td></tr><tr><td>Lab coat</td><td></td><td></td><td></td></tr><tr><td>Monoject 1 mL hypodermic syringe</td><td>Coviden</td><td>8881501400</td><td></td></tr><tr><td>Moria iris forceps, curved, serrated (x2)</td><td>Fine Science Tools</td><td>11370-31</td><td></td></tr><tr><td>Moria speculum retractor</td><td>Fine Science Tools</td><td>17370-53</td><td></td></tr><tr><td>Mouse endotracheal intubation kit</td><td>Kent Scientific</td><td></td><td></td></tr><tr><td>Nair depilatory cream</td><td>Johnson &amp;amp; Johnson</td><td></td><td>Fur removal</td></tr><tr><td>Optixcare eye lube plus</td><td>Aventix</td><td></td><td>Sterile ocular lubricant</td></tr><tr><td>Physiosuite ventilator</td><td>Kent Scientific</td><td></td><td></td></tr><tr><td>PolyE Polyethylene tubing</td><td>Harvard Apparatus</td><td>72-0191</td><td>Temporary compression of LAD artery</td></tr><tr><td>Povidone-iodine swabs</td><td>PDI</td><td>S41125</td><td></td></tr><tr><td>Scalpel, 10-blade</td><td>Bard-Parker</td><td>371610</td><td></td></tr><tr><td>Sterile 3&quot; cotton tipped applicators</td><td>Cardinal Health</td><td>C15055-003</td><td></td></tr><tr><td>Sterile 6&quot; tapered cotton tip applicators</td><td>Puritan</td><td>25-826-5WC</td><td></td></tr><tr><td>Sterile gloves</td><td>Cardinal Health</td><td>N8830</td><td></td></tr><tr><td>Sterilization pouches</td><td>Medline</td><td>MPP100525GS</td><td></td></tr><tr><td>Surgery cap</td><td></td><td></td><td></td></tr><tr><td>Surgical Microscope</td><td>Leica</td><td>M125</td><td></td></tr><tr><td>Suture tying forceps, straight (x2)</td><td>Fine Science Tools</td><td>10825-10</td><td></td></tr><tr><td>Transpore surgical tape</td><td>3M</td><td>1527-1</td><td></td></tr><tr><td>Triple antibiotic ointment</td><td>G&amp;amp;W Laboratories</td><td>11-2683ILNC2</td><td>Topical application to prevent infection</td></tr><tr><td>Vannas-T&amp;uuml;bingen Spring Scissors, curved</td><td>Fine Science Tools</td><td>15004-08</td><td></td></tr><tr><td>Vetflo vaporizer</td><td>Kent Scientific</td><td></td><td></td></tr></tbody></table>

delayed intramyocardial delivery of stem cells after ischemia reperfusion injury in a murine model

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

There is significant interest in the use of stem cells (SCs) for the recovery of cardiac function in individuals with myocardial injuries. Most commonly, cardiac stem cell therapy is studied by delivering SCs concurrently with the induction of myocardial injury. However, this approach presents two significant limitations: the early hostile pro-inflammatory ischemic environment may affect the survival of transplanted SCs, and it does not represent the subacute infarction scenario where SCs will likely be used. Here we describe a two-part series of surgical procedures for the induction of ischemia-reperfusion injury and delivery of mesenchymal stem cells (MSCs). This method of stem cell administration may allow for the longer viability and retention around damaged tissue by circumventing the initial immune response. A model of ischemia reperfusion injury was induced in mice accompanied by the delivery of mesenchymal stem cells (3.0 x 105), stably expressing the reporter gene firefly luciferase under the constitutively expressed CMV promoter, intramyocardially 7 days later. The animals were imaged via ultrasound and bioluminescent imaging for confirmation of injury and injection of cells, respectively. Importantly, there was no added complication rate when performing this two-procedure approach for SC delivery. This method of stem cell administration, collectively with the utilization of state-of-the-art reporter genes, may allow for the in vivo study of viability and retention of transplanted SCs in a situation of chronic ischemia commonly seen clinically, while also circumventing the initial pro-inflammatory response. In summary, we established a protocol for the delayed delivery of stem cells into the myocardium, which can be used as a potential new approach in promoting regeneration of the damaged tissue.

Ischemia reperfusion injury was induced in mice on day 0, followed by a post-operative echocardiogram and electrocardiogram on the day preceding stem cell implantation. Ultrasound and electrocardiogram analysis confirmed infarction and decreased ventricular contractile function (Figure 1A-D). Further examination of the data showed the ejection fraction and fractional shortening were decreased in mice that received ischemic injury, while the end-diastolic and systolic volumes...

Stems cells are continuously investigated as potential treatments for individuals with myocardial damage, however, their decreased viability and retention within injured tissue can impact their long-term efficacy. In this manuscript we describe an alternative method for stem cell delivery in a murine model of ischemia reperfusion injury.

There is significant interest in the use of stem cells (SCs) for the recovery of cardiac function in individuals with myocardial injuries. Most commonly, ...

delayed-intramyocardial-delivery-stem-cells-after-ischemia

Research

JoVE Journal

Medicine

This video demonstrates how to use a fast and reliable model to study pathobiological and pathophysiological processes of myocardial ischemia.

LAD-Ligation: A Murine Model of Myocardial Infarction

Numerous genetic manipulations and/or intramyocardial injections of genes, proteins, cells, and/or biomaterials are superimposed upon the dimension of time in studies of acute ischemia/ reperfusion injury and chronic remodeling in mice.  This video illustrates the microsurgical procedures for ischemia/reperfusion, permanent coronary artery ligation, and intramyocardial injection studies.

Coronary Artery Ligation and Intramyocardial Injection in a Murine Model of Infarction

Intramyocardial cell delivery in murine models of cardiovascular diseases, such as hypertension or myocardial infarction, is widely used to test the therapeutic potential of different cell types in regenerative studies. Therefore, a detailed description and a clear visualization of this surgical procedure will help to define the limits and advantages of cardiovascular cell therapeutic analyses in small rodents.

Intramyocardial Cell Delivery: Observations in Murine Hearts

Echocardiography-guided percutaneous intramyocardial injection represents an efficient, reliable, and targetable modality for the delivery of gene transfer agents or cells into the murine heart. Following the steps outlined in this protocol, the operator can quickly become competent in this versatile, minimally invasive technique.

Ultrasound-guided Transthoracic Intramyocardial Injection in Mice

Novel therapeutic strategies in cardiac regenerative medicine require extensive and detailed studies in large preclinical animal models before they can be considered for use in humans. Here, we demonstrate a percutaneous contrast echocardiography-guided intramyocardial injection technique in rabbits, which is valuable for hypothesis testing the efficacy of such novel therapies.

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

We sought to establish a swine model of heart failure induced by left circumflex artery blockage and rapid pacing to test the effect and safety of intramyocardial administration of stem cells for cell-based therapies.

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Stem cell-based therapy has emerged as an efficient strategy to repair injured cardiac tissues after myocardial infarction. We provide an optimal in vivo application for stem cell transplantation using gelatin hydrogels that are able to be enzymatically cross-linked.

Intramyocardial Transplantation of MSC-Loading Injectable Hydrogels after Myocardial Infarction in a Murine Model

Ultrasound-guided cell delivery around the site of myocardial infarction in mice is a safe, effective, and convenient way of cell transplantation.

Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice

This article details an optimized protocol for echocardiography-guided intramyocardial injections in rat models of myocardial infarction using a 29 G x 88 mm needle. This technique ensures robust, precise, and reproducible delivery of therapeutic agents directly into the peri-infarct zone.

Echocardiography-guided Injection for Targeted and Reliable Intramyocardial Stem Cell Delivery in a Rat Model of Myocardial Infarction

We demonstrate how to set up an in vitro ischemia/reperfusion model and how to evaluate the effect of stem cell therapy on postischemic cardiac cells.

Stem Cell Transplantation in an in vitro Simulated Ischemia/Reperfusion Model

Discover a method for delayed intramyocardial stem cell delivery in a murine ischemia reperfusion injury model. This technique circumvents the initial immune response to improve cell viability and retention.

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Explore More Videos